57M now covered for BrainsWay (NASDAQ: BWAY) accelerated Deep TMS
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
BrainsWay Ltd. reported a major expansion of insurance coverage for its SWIFT™ Accelerated Deep TMS™ protocol in the United States. Following several favorable policy changes, including a newly issued policy covering 2 million members in South Carolina, more payers now reimburse this accelerated treatment approach.
With these updates, eight major payers and the U.S. Department of Veterans Affairs now either cover or include policy language supporting accelerated TMS treatment approaches, representing over 57 million covered lives. Management highlights this as evidence of growing adoption of Deep TMS therapies and broader patient access.
The company positions itself as a leader in noninvasive neurostimulation, with its Deep TMS platform cleared by the FDA for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. BrainsWay emphasizes ongoing clinical research and collaboration with providers and policymakers to further expand access to its treatments.
Positive
- None.
Negative
- None.
Key Figures
Covered lives for accelerated TMS: over 57 million covered lives
New South Carolina policy members: 2 million members
FDA-cleared Deep TMS indications: three indications
+1 more
4 metrics
Covered lives for accelerated TMS
over 57 million covered lives
Eight major payers plus U.S. Department of Veterans Affairs
New South Carolina policy members
2 million members
Recently issued policy allowing coverage of SWIFT
FDA-cleared Deep TMS indications
three indications
Major depressive disorder, obsessive-compulsive disorder, smoking addiction
Year founded
2003
BrainsWay founding year mentioned in company background
Key Terms
SWIFT™ Accelerated Deep TMS™ protocol, Deep Transcranial Magnetic Stimulation (Deep TMS™), major depressive disorder, obsessive-compulsive disorder, +1 more
5 terms
SWIFT™ Accelerated Deep TMS™ protocol medical
"providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol"
Deep Transcranial Magnetic Stimulation (Deep TMS™) medical
"proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology"
major depressive disorder medical
"Deep TMS coverage for both major depressive disorder (MDD) and obsessive-compulsive disorder (OCD) patients"
A clinical condition characterized by persistent, severe low mood, loss of interest in daily activities, and reduced ability to function at work or home, lasting weeks or longer. It matters to investors because it drives demand for treatments and mental health services, affects workforce productivity and absenteeism, influences health-care and insurance costs, and shapes risks and opportunities for companies developing drugs, therapies or workplace programs—like a long-lasting storm that lowers economic output.
obsessive-compulsive disorder medical
"Deep TMS coverage for both major depressive disorder (MDD) and obsessive-compulsive disorder (OCD) patients"
Obsessive-compulsive disorder (OCD) is a mental health condition marked by unwanted, repetitive thoughts (obsessions) and time-consuming actions or rituals (compulsions) performed to ease anxiety. For investors, OCD matters because it influences demand for medical treatments, therapy services, and workplace accommodations, and can affect productivity, healthcare costs, and the commercial potential of drugs or devices aimed at managing the condition — much like how a chronic physical illness shapes markets and spending.
forward-looking statements regulatory
"This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What did BrainsWay (BWAY) announce in its June 2026 Form 6-K?
BrainsWay announced expanded U.S. insurance coverage for its SWIFT Accelerated Deep TMS protocol. Several medical policy updates now support accelerated TMS approaches, increasing reimbursement access for patients needing Deep TMS therapies for conditions like major depressive disorder and obsessive-compulsive disorder.
How many covered lives now have favorable access to BrainsWay’s accelerated Deep TMS?
BrainsWay reports that favorable coverage or supportive policy language for accelerated TMS approaches now represents over 57 million covered lives. This includes coverage from eight major payers plus the U.S. Department of Veterans Affairs across multiple U.S. markets.
Which new policy change did BrainsWay highlight in South Carolina?
BrainsWay highlighted a newly issued medical policy in South Carolina covering 2 million members. This policy allows coverage of the company’s SWIFT Accelerated Deep TMS protocol, adding to broader Deep TMS coverage for major depressive disorder and obsessive-compulsive disorder patients.
Which conditions are FDA-cleared for BrainsWay’s Deep TMS platform?
BrainsWay’s Deep TMS platform has three FDA-cleared indications. These are major depressive disorder, including anxious depression, obsessive-compulsive disorder, and smoking addiction, each backed by pivotal clinical studies demonstrating clinically proven efficacy according to the company.
How does BrainsWay describe the significance of the new coverage for SWIFT?
BrainsWay’s CEO says the milestone underscores accelerating adoption of SWIFT and broader momentum toward improving access to Deep TMS. The company links this expansion to its growing clinical evidence base and continuing efforts to secure additional coverage for evidence-based neurostimulation treatments.